An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The clinical development of an inhibitor of cellular proteasome function suggests that compounds targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies. NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome. Substrates of cullin-RING ligases have important roles in cellular processes associated with cancer cell growth and survival pathways. Here we describe MLN4924, a potent and selective inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis. MLN4924 suppressed the growth of human tumour xenografts in mice at compound exposures that were well tolerated. Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“orthogonally confirmed dose-dependent KAT2A degradation by western blot, and demonstrated that this degradation can be rescued by pre-treatment with a UBA3/NAE1 inhibitor, MLN4924 (37), a proteasome inhibitor, bortezomib (38), and a competing CRBN ligand, pomalidomide (7) (Fig. 1D).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [37]
In the citing paper
“we cotreated cells with a proteasome inhibitor (bortezomib) or a NEDD8-activating enzyme E1 inhibitor (MLN-4924 32 ) and found that both inhibitors prevented degradation of BTK (Figure 2D).”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [32]
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Cited by
Items 901–1,000 of 1,005
Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential
Wu, K., Huynh, K. Q., Lu, I., Moustakim, M., Miao, H., Yu, C., Haeusgen, M. J., Hopkins, B. D., Huang, L., Zheng, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007328118 · Cited by 30
Song, J., Liu, Y., Yuan, X., Liu, W., Li, Y.-R., Yu, G.-X., Tian, X.-Y., Zhang, Y., Fu, X.-J., & Zhang, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113801 · Cited by 26
The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway
Tang, H., Pang, X., Li, S., & Tang, L. (2024) · Biomolecules · doi:10.3390/biom14070738 · Cited by 25
Proteasome inhibition and its therapeutic potential in multiple myeloma
Chari, A., Mazumder, A., & Jagannath, S. (2010) · Biologics · doi:10.2147/btt.s3419 · Cited by 29
Fu, S.-J., Hu, M., Peng, Y.-J., Fang, H.-Y., Hsiao, C.-T., Chen, T., Jeng, C., & Tang, C. (2020) · Cells · doi:10.3390/cells9061332 · Cited by 25
Petillo, S., Capuano, C., Molfetta, R., Fionda, C., Mekhloufi, A., Pighi, C., Antonangeli, F., Zingoni, A., Soriani, A., Petrucci, M. T., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04104-w · Cited by 26
Adenovirus prevents dsRNA formation by promoting efficient splicing of viral RNA
Price, A. M., Steinbock, R. T., Di, C., Hayer, K. E., Li, Y., Herrmann, C., Parenti, N. A., Whelan, J. N., Weiss, S. R., & Weitzman, M. D. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab896 · Cited by 27
Confettura, A. D., Cuboni, E., Ammar, M. R., Jia, S., Gomes, G. M., Yuanxiang, P., Raman, R., Li, T., Grochowska, K. M., Ahrends, R., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-021-00277-8 · Cited by 25
Murer, L., Volle, R., Andriasyan, V., Petkidis, A., Gómez-González, A., Yang, L., Meili, N., Suomalainen, M., Bauer, M., Sequeira, D. P., et al. (2022) · Current Research in Virological Science · doi:10.1016/j.crviro.2022.100019 · Cited by 25
The ubiquitin ligase Cul5 regulates CD4+ T cell fate choice and allergic inflammation
Kumar, B., Field, N. S., Kim, D. D., Dar, A. A., Chen, Y., Suresh, A., Pastore, C., Hung, L., Porter, N., Sawada, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30437-x · Cited by 27
Mehine, M. M., Ahvenainen, T., Khamaiseh, S., Härkönen, J., Reinikka, S., Heikkinen, T., Äyräväinen, A., Pakarinen, P. I., Härkki, P., Pasanen, A. M., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00425-3 · Cited by 26
Wang, J., Ferrena, A., Zhang, R., Singh, S., Viscarret, V., Al-Harden, W., Aldahamsheh, O., Borjihan, H., Singla, A. K., Yaguare, S., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02942-4 · Cited by 26
A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness
Grau, L., Luque-Garcia, J. L., González‐Peramato, P., Theodorescu, D., Palou, J., Gómez, J. M. F., & Sänchez‐Carbayo, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053328 · Cited by 25
Sandoval, D., Hill, S., Ziemba, A. J., Lewis, S. M., Kuhlman, B. A., & Kleiger, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.615559 · Cited by 29
Armitage, I., Berne, A. M., Elliott, E. L., Fu, M., Hicks, F. A., McCubbin, Q. J., & Zhu, L. (2012) · Organic Letters · doi:10.1021/ol3009683 · Cited by 25
Nedd8 targets ubiquitin ligase Smurf2 for neddylation and promote its degradation
Shu, J., Liu, C., Wei, R., Xie, P., He, S., & Zhang, L. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.058 · Cited by 25
Tan, S., Liu, F., Pan, X., Zang, Y., Jin, F., Zu, W.-X., Qi, X., Xiao, W., & Yin, L. (2016) · Scientific Reports · doi:10.1038/srep25485 · Cited by 25
Singh, R. K., Kazansky, Y., Wathieu, D., & Fushman, D. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04194 · Cited by 27
Design, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives
Kılıç-Kurt, Z., Bakar‐Ates, F., Aka, Y., & Kütük, Ö. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.060 · Cited by 25
On the Mechanism of Hyperthermia-Induced BRCA2 Protein Degradation
van den Tempel, N., Zelensky, A. N., Odijk, H., Laffeber, C., Schmidt, C. K., Brandsma, I., Demmers, J., Krawczyk, P. M., & Kanaar, R. (2019) · Cancers · doi:10.3390/cancers11010097 · Cited by 26
RNF126 as a Marker of Prognosis and Proliferation of Gastric Cancer
Migita, K., Matsumoto, S., Wakatsuki, K., Kunishige, T., Nakade, H., Miyao, S., & Sho, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14078 · Cited by 25
Schweitzer, K., Pralow, A., & Naumann, M. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12702 · Cited by 28
Chai, R., Yu, X., Tu, S., & Zheng, B. (2016) · Tumor Biology · doi:10.1007/s13277-016-5159-y · Cited by 25
A Quantitative Genetic Interaction Map of HIV Infection
Gordon, D. E., Watson, A., Roguev, A., Zheng, S., Jang, G. Μ., Kane, J., Xu, J., Guo, J. Z., Stevenson, E. J., Swaney, D. L., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.02.004 · Cited by 29
The Ubiquitin-Proteasome System (UPS) as a Cancer Drug Target: Emerging Mechanisms and Therapeutics
Mata-Cantero, L., Lobato-Gil, S., Aillet, F., Lang, V., & Rodríguez, M. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_11 · Cited by 29
Activation of Ubiquitin and Ubiquitin-Like Proteins
Streich, F. C., & Haas, A. L. (2010) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4419-6676-6_1 · Cited by 25
Chang, Y., Chen, Q., Li, H., Xu, J., Tan, M., Xiong, X., & Sun, Y. N. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.03.018 · Cited by 27
Pan, M., Yang, C., Fu, Z., Yang, Y., Zhuo, Y., Hou, H., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202501384 · Cited by 27
Zhou, W., Xu, C., Dong, G., Qiao, H., Yang, J. C., Liu, H., Ding, L., Sun, K., & Zhao, W. H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113326 · Cited by 24
AMBRA1 Promotes TGFβ Signaling via Nonproteolytic Polyubiquitylation of Smad4
Liu, J., Yuan, B., Cao, J., Luo, H., Gu, S., Zhang, M., Ding, R., Zhang, L., Zhou, F., Hung, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0431 · Cited by 26
Zhang, Y., Jost, M., Pak, R. A., Lu, D., Li, J., Lomenick, B., Garbis, S. D., Li, C.-M., Weissman, J. S., Lipford, J. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205608119 · Cited by 30
LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
Ko, A., Hasanain, M., Oh, Y. T., D’Angelo, F., Sommer, D., Frangaj, B., Tran, S., Bielle, F., Pollo, B., Paterra, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0376 · Cited by 26
The β-catenin E3 ubiquitin ligase SIAH-1 is regulated by CSN5/JAB1 in CRC cells
Jumpertz, S., Hennes, T., Asare, Y., Vervoorts, J., Bernhagen, J., & Schütz, A. K. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.013 · Cited by 25
Shinde, V., Burke, K. E., Chakravarty, A., Fleming, M. D., McDonald, A. A., Berger, A., Ecsedy, J., Blakemore, S. J., Tirrell, S. M., & Bowman, D. (2013) · Veterinary Pathology · doi:10.1177/0300985813511124 · Cited by 24
Self-citationLeclerc, G. M., Zheng, S., Leclerc, G. J., DeSalvo, J., Swords, R. T., & Barredo, J. C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.007 · Cited by 24
Neutrophils and the inflammatory tissue microenvironment in the mucosa
Campbell, E. L., Kao, D. J., & Colgan, S. P. (2016) · Immunological Reviews · doi:10.1111/imr.12456 · Cited by 28
Picco, G., Petti, C., Sassi, F. P., Grillone, K., Migliardi, G., Rossi, T., Isella, C., Nicolantonio, F. D., Sarotto, I., Sapino, A., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw209 · Cited by 27
Advancing our Understanding of Ubiquitination Using the Ub-Toolkit
Witting, K. F., Mulder, M. P. C., & Ovaa, H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.002 · Cited by 25
Xu, B., Deng, Y., Bi, R., Guo, H., Shu, C., Shah, N. K., Chang, J., Liu, G., Du, Y., Wei, W., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3582-z · Cited by 27
Hong, X., Li, S., Li, W., Xie, M., Wei, Z., Guo, H., Wei, W., & Zhang, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.048 · Cited by 24
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C., Fang, L., Jiang, P., Yin, L., Zhang, L., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7098 · Cited by 24
Self-citationRetractedCul4A Modulates Invasion and Metastasis of Lung Cancer through Regulation of ANXA10
Hung, M., Chen, Y.-C., Lin, P.-Y., Li, Y., Hsu, C.-C., Lung, J., You, L., Xu, Z., Mao, J., Jablons, D. M., et al. (2019) · Cancers · doi:10.3390/cancers11050618 · Cited by 24
Song, J., Cui, X., Wu, B., Li, D., Wang, S.-H., Shi, L., Zhu, T., Zhang, Y., & Zhang, S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126791 · Cited by 24
Han, S., Shin, H., Oh, J.-W., Oh, Y. J., Her, N.-G., & Nam, D. (2019) · Cancers · doi:10.3390/cancers11121849 · Cited by 24
COP9 Signalosome Suppresses RIPK1-RIPK3–Mediated Cardiomyocyte Necroptosis in Mice
Xiao, P., Wang, C., Lewno, M. T., Su, H., Li, J., Wu, P., Sternburg, J. O., Liu, J., & Wang, X. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.006996 · Cited by 26
The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance
Du, M., Peng, Z., Gai, W., Liu, F., Liu, W., Chen, Y., Li, H., Zhang, X., Liu, C. H., Zhang, L.-Q., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667435 · Cited by 25
Enrico, T. P., Stallaert, W., Wick, E. T., Ngoi, P., Wang, X., Rubin, S. M., Brown, N. G., Purvis, J. E., & Emanuele, M. J. (2021) · eLife · doi:10.7554/elife.70691 · Cited by 26
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201611281 · Cited by 24
MLN4924, a First-in-Class NEDD8-Activating Enzyme Inhibitor, Attenuates IFN-β Production
Song, H., Huai, W., Yu, Z., Wang, W., Zhao, J., Zhang, L., & Zhao, W. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501752 · Cited by 27
Schultz, T. E., Mathmann, C. D., Cadena, L. C. D., Muusse, T. W., Kim, H., Wells, J. W., Ulett, G. C., Hamerman, J. A., Brooks, A. J., Kobe, B., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00444-2 · Cited by 26
SCFβ-TRCP E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation
Ci, Y., Li, X., Chen, M., Zhong, J., North, B. J., Inuzuka, H., He, X., Li, Y., Guo, J., & Dai, X. (2018) · Protein & Cell · doi:10.1007/s13238-018-0510-2 · Cited by 24
Kinterová, V., Kaňka, J., Petruskova, V., & Toralová, T. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy254 · Cited by 23
Chen, Y., & Sun, L. (2022) · Bioscience Reports · doi:10.1042/bsr20220994 · Cited by 23
Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA
Brewer, A., Sathe, G. J., Pflug, B. E., Clarke, R. G., Macartney, T., & Sapkota, G. P. (2024) · iScience · doi:10.1016/j.isci.2024.109302 · Cited by 30
Diffuse large B cell lymphoma: molecular targeted therapy
Roschewski, M. J., Dunleavy, K. M., & Wilson, W. H. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1198-3 · Cited by 25
Identification of quinazolinyloxy biaryl urea as a new class of SUMO activating enzyme 1 inhibitors
Kumar, A., Ito, A., Hirohama, M., Yoshida, M., & Zhang, K. Y. J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.022 · Cited by 23
Characterization of the role of COP9 signalosome in regulating cullin E3 ubiquitin ligase activity
Choo, Y. Y., Boh, B. K., Lou, J. J. W., Eng, J., Leck, Y. C., Anders, B., Smith, P. G., & Hagen, T. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-03-0251 · Cited by 23
Self-citationFingerprinting differential active site constraints of ATPases
Hacker, S. M., Hardt, N., Buntru, A., Pagliarini, D., Möckel, M. M., Mayer, T. U., Scheffner, M., Hauck, C. R., & Marx, A. (2013) · Chemical Science · doi:10.1039/c3sc21916j · Cited by 27
Insights Into the Allosteric Inhibition of the SUMO E2 Enzyme Ubc9
Hewitt, W. M., Lountos, G. T., Zlotkowski, K., Dahlhauser, S. D., Saunders, L. B., Needle, D., Tropea, J. E., Zhan, C., Wei, G., Ma, B., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511351 · Cited by 23
Khilwani, B., Mukhopadhaya, A., & Chattopadhyay, K. (2014) · Biochemical Journal · doi:10.1042/bj20140718 · Cited by 23
Lin, W., Kuo, K.-L., Shi, C., Wu, J., Hsieh, J., Chang, H., Liao, S.-M., Chou, C.-T., Chiang, C., Chiu, W.-S., et al. (2015) · PubMed · Cited by 23
Distinct outcomes of CRL–Nedd8 pathway inhibition reveal cancer cell plasticity
Rulina, A. V., Mittler, F., Obeïd, P., Gerbaud, S., Guyon, L., Sulpice, E., Kermarrec, F., Assard, N., Dolega, M. E., Gidrol, X., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.395 · Cited by 23
Regulation of Mammalian DNA Replication via the Ubiquitin-Proteasome System
Abbas, T., & Dutta, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6955-0_19 · Cited by 26
Sun, X., Tong, X., Hao, Y., Li, C., Zhang, Y., Pan, Y., Dai, Y., Liu, L., Zhang, T., & Zhang, S. (2020) · Molecular Human Reproduction · doi:10.1093/molehr/gaaa021 · Cited by 23
Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer
Gâtel, P., Piechaczyk, M., & Bossis, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_2 · Cited by 23
SUMO proteins in the cardiovascular system: friend or foe?
Shetty, P. M. V., Rangrez, A. Y., & Frey, N. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00689-0 · Cited by 23
Posttranslational modifications of lysine and evolving role in heart pathologies—Recent developments
Št́astná, M., & Eyk, J. E. V. (2014) · PROTEOMICS · doi:10.1002/pmic.201400312 · Cited by 24
Lachiondo‐Ortega, S., Mercado-Gómez, M., Serrano‐Maciá, M., Lopitz‐Otsoa, F., SALAS-VILLALOBOS, T. B., Varela‐Rey, M., Delgado, T. C., & Martínez‐Chantar, M. L. (2019) · Cells · doi:10.3390/cells8121575 · Cited by 23
Lucas, S. C. C., Ahmed, A., Ashraf, S. N., Argyrou, A., Bauer, M. R., Donatis, G. M. D., Demanze, S., Eisele, F., Fusani, L., Hock, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02136 · Cited by 25
FBXO22 promotes HCC angiogenesis and metastasis via RPS5/AKT/HIF-1α/VEGF-A signaling axis
Lei, Z., Luo, Y., Lu, J., Fu, Q., Wang, C., Chen, Q., Zhang, Z., & Zhang, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-024-00861-w · Cited by 25
Jackson, K. L., Yin, N., Agafonov, R. V., Chaturvedi, P., Cole, K. S., Eron, S. J., Good, A. C., Hart, J. A., He, M., Henderson, C. S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01317 · Cited by 24
SPIN4 Is a Principal Endogenous Substrate of the E3 Ubiquitin Ligase DCAF16
Zhang, X., Thielert, M., Li, H., & Cravatt, B. F. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00067 · Cited by 23
Adenovirus Remodeling of the Host Proteome and Host Factors Associated with Viral Genomes
Dybas, J. M., Lum, K. K., Kulej, K., Reyes, E. D., Lauman, R., Charman, M., Purman, C. E., Steinbock, R. T., Grams, N., Price, A. M., et al. (2021) · mSystems · doi:10.1128/msystems.00468-21 · Cited by 27
Yaagoubi, O. M. E., Oularbi, L., Bouyahya, A., Samaki, H., Antri, S. E., & Aboudkhil, S. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1978785 · Cited by 24
A ubiquitin-independent proteasome pathway controls activation of the CARD8 inflammasome
Hsiao, J. C., Neugroschl, A. R., Chui, A. J., Taabazuing, C. Y., Griswold, A. R., Wang, Q., Huang, H., Orth-He, E. L., Ball, D. P., Hiotis, G., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102032 · Cited by 22
The p97 segregase cofactor Ubxn7 facilitates replisome disassembly during S-phase
Tarcan, Z. C., Poovathumkadavil, D., Skagia, A., & Gambus, A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102234 · Cited by 22
Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
Darvishi, E., Ghamsari, L., Leong, S. F., Ramirez, R., Koester, M., Gallagher, E., Yu, M., Mason, J. M., Merutka, G., Kappel, B. J., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0962 · Cited by 23
Jiang, H., Bian, W., Sui, Y., Li, H., Zhao, H., Wang, W., & Li, X. (2022) · Science Advances · doi:10.1126/sciadv.abq4831 · Cited by 24
Torka, P., Kambhampati, S., Chen, L., Wang, X., Chen, C., Vuong, D., Qin, H., Muir, A., Orand, K., Borja, I., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00763-w · Cited by 22
Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review
Jia, J., Li, R., Junyuan, S., Yang, J., Zhihao, H., Weiguo, L., & Jia, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122008 · Cited by 23
Tian, Y., Milic, J., Monasor, L. S., Chakraborty, R., Wang, S., Yuan, Y., Asare, Y., Behrends, C., Tahirović, S., & Bernhagen, J. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04911-8 · Cited by 23
Qin, A., Wells, L., Malhotra, B., Gadgeel, S. M., Schneider, B. J., Ramnath, N., Rice, J. D., & Kalemkerian, G. P. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.10.011 · Cited by 22
The solute carrier superfamily interactome
Frommelt, F., Ladurner, R., Goldmann, U., Wolf, G., Inglés‐Prieto, Á., Liñeiro, E., Gelová, Z., Hopp, A.-K., Christodoulaki, E., Teoh, S. T., et al. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00109-1 · Cited by 22
The bacterial pathogen-ubiquitin interface: lessons learned fromShigella
Tanner, K., Brzović, P. S., & Rohde, J. R. (2014) · Cellular Microbiology · doi:10.1111/cmi.12390 · Cited by 22
Naidu, P. S., & Bhuyan, P. J. (2014) · RSC Advances · doi:10.1039/c3ra47143h · Cited by 22
Boh, B. K., Ng, M. Y., Leck, Y. C., Shaw, B., Long, J., Sun, G. W., Gan, Y., Searle, M. S., Layfield, R., & Hagen, T. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.08.030 · Cited by 22
Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4DCAF1
Li, W., & Giancotti, F. G. (2010) · Cell Cycle · doi:10.4161/cc.9.22.13838 · Cited by 26
Wong, K. M., Micel, L. N., Selby, H. M., Tan, A. C., Pitts, T. M., Bagby, S. M., Spreafico, A., Klauck, P. J., Blakemore, S. J., Smith, P. G., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0398-8 · Cited by 22
Self-citationCSNAP, the smallest CSN subunit, modulates proteostasis through cullin-RING ubiquitin ligases
Füzesi-Levi, M. G., Fainer, I., Enchev, R. I., Ben‐Nissan, G., Levin, Y., Kupervaser, M., Friedlander, G., Salame, T. M., Nevo, R., Peter, M., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0392-8 · Cited by 24
Jeng, C., Fu, S.-J., You, C.-Y., Peng, Y.-J., Hsiao, C.-T., Chen, T., & Tang, C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00076 · Cited by 25
Yang, C., Hsu, H., Chang, H.-Y., Lee, Y., & Lee, S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114122 · Cited by 24
Costanzo, A. D., Gaudio, N. D., Conte, L., & Altucci, L. (2020) · Cancers · doi:10.3390/cancers12071898 · Cited by 24
Degradation of Transcriptional Repressor ATF4 during Long-Term Synaptic Plasticity
Smith, S. G., Haynes, K. A., & Hegde, A. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228543 · Cited by 23
Mashima, T., Ushijima, M., Matsuura, M., Tsukahara, S., Kunimasa, K., Furuno, A., Saito, S., Kitamura, M., Soma‐Nagae, T., Seimiya, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12682 · Cited by 22
Skp2 knockout reduces cell proliferation and mouse body size: and prevents cancer?
Zhu, L. (2010) · Cell Research · doi:10.1038/cr.2010.71 · Cited by 22
Zhou, X., Han, S., Wilder-Romans, K., Sun, G. Y., Zhu, H., Liu, X., Tan, M., Wang, G., Feng, F. Y.-C., & Sun, Y. (2020) · Neoplasia · doi:10.1016/j.neo.2020.02.002 · Cited by 22
Maher, K. R., Shafer, D. A., Schaar, D. G., Bandyopadhyay, D., Deng, X., Wright, J., Piekarz, R., Rudek, M. A., Harvey, R. D., & Grant, S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04742-9 · Cited by 25
Chen, Y., Du, M., Yusuying, S., Liu, W., Tan, Y., & Xie, P. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112038 · Cited by 21
Klaessens, S., Stroobant, V., Hoffmann, D., Gyrd‐Hansen, M., Pilotte, L., Vigneron, N., Plaen, E. D., & den Eynde, B. J. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022447118 · Cited by 22
He, Z., An, Q., Wei, B., Zhou, W., Wei, B., Gong, Y., Zhang, X., Gao, G., Dong, G., Huo, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01207 · Cited by 22
Metadata
- Authors
- Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., & Langston, S. P.
- Affiliations
- Takeda Oncology (United States) (US)
- Corresponding author
- Soucy, Teresa A.
- ORCID
- Venue
- Nature
- Published
- 2009-04
- Volume
- 458
- Issue
- 7239
- Pages
- 732-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2076194625
- Cited by
- 1,990
- References
- 46
- Citations by year
- 2026: 110 · 2025: 120 · 2024: 156 · 2023: 126 · 2022: 137 · 2021: 155 · 2020: 170 · 2019: 149 · 2018: 112 · 2017: 105 · 2016: 108 · 2015: 98 · 2014: 99 · 2013: 100 · 2012: 100
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, MLN4924, cullin-RING ubiquitin ligases, ubiquitin-proteasome system, proteasome inhibitors, cancer cell death, tumor xenografts, small molecule inhibitors, antitumour activity
- MeSH terms
- NEDD8 Protein, Animals, Antineoplastic Agents, Cells, Cultured, Cyclopentanes, Enzyme Inhibitors, Female, Humans, Neoplasms, Pyrimidines, Transplantation, Heterologous, Ubiquitins, Ubiquitin-Activating Enzymes, Cullin Proteins, Cell Line, Tumor, Mice, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.